Clinical Trials
A randomized, double- blinded, balanced, two-treatments, two-periods, two-sequences, single dose, crossover, pharmacokinetics and pharmacodynamics (PK/PD), safety and immunogenicity study of Epoetin (Erythropoietin 4000 IU Injection) for subcutaneous injection manufactured by Incepta Pharmeceuticals Ltd with Eprex 4000 (Epoetin Alfa) injectable solution for subcutaneous injection manufactured by Janssen-Cilag Ltd in 56 healthy adult subjects under fasting condition.
Principal Investigator: Dr. Umme Kulsum, Assistant Scientist, Institute for Developing Science and Health Initiatives (ideSHi)CRO: Institute for developing science and health initiatives (ideSHi),
Application Date: 1 Dec, 2024
Test
Principal Investigator: testCRO: Advance Bioresearch Solution-BD
Application Date: 8 Oct, 2024
An Observer-blind, Randomized, Active-controlled, Multi-centric Phase III Study in Infants and Toddlers to assess the Immunogenicity and Safety of SIIPL HEXAVALENT (DTwp-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV in comparison with SIIPL HEXASIIL.
Principal Investigator: Dr. K. ZamanCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 23 Apr, 2024
Testing the role of thermal jacket in attaining and maintaining Euthermia among preterm and LBW neonates in clinical settings of Bangladesh "
Principal Investigator: Anisuddin AhmedCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 11 Jan, 2024
Randomized Control Trial of Nitazoxanide for the Treatment of Cryptosporidium Infection in 6-12 months infant in Bangladesh.
Principal Investigator: Dr Rashidul HaqueCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 27 Dec, 2023
An open label, randomized, laboratory blind single dose two period two treatment two sequence, two-way crossover comparative oral bioavailability study of test product Telmisartan and hydrochlorothiazide (hctz) tablet 80/12.5 mg of Beximco Pharmaceuticals Limited, Bangladesh with reference product Micardis plus 80/12.5 tablet ie Telmisartan and hydrochlorothiazide (hctz) 80/12.5mg of Boehringer Ingelheim PTY Limited, Sydney, Australia in healthy adult male subjects under fasting conditions
Principal Investigator: Dr Uttam K BhowmikCRO: M/S. Novas Clinical Research Services Ltd. (NCRSL),
Application Date: 26 Dec, 2023
An open label, randomized, laboratory blind, single dose, two period, two treatment, two sequence, two-way crossover, comparative oral bioavailability study of test product Montelukast Sodium 10 mg tablet of Beximco Pharmaceuticals Limited, Bangladesh with reference product Singulair 10 (Montelukast Sodium 10 mg) Tablet of Organo Pharma PTY Ltd, Australia, in healthy adult human subjects under fasting conditions
Principal Investigator: Dr Uttam K BhowmikCRO: M/S. Novas Clinical Research Services Ltd. (NCRSL),
Application Date: 12 Dec, 2023
An open label randomized laboratory blind single dose, two period, two treatment, two sequence, two - way crossover comparative oral bioavailability study of test product Vonoprazan Fumarate 20 mg tablet of Beximco Pharmaceuticals Limited, Bangladesh with reference product Takecab 20 mg tablet I.E Vonoprazan Fumar 20 mg of Takeda Pharmaceutical Company Limited, Japan in healthy adult human subjects under fasting conditions
Principal Investigator: Dr Uttam K BhowmikCRO: M/S. Novas Clinical Research Services Ltd. (NCRSL),
Application Date: 29 Nov, 2023
A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Age De-escalation, Dose Combination Ranging Study to Assess the Safety and Immunogenicity of Co-administered Novel Live Attenuated Trivalent Oral Poliomyelitis Vaccine in Healthy Adults, Young Children, and Neonates and Co-administered Novel Live Attenuated Monovalent Oral Poliomyelitis Vaccines 1 and 2 in Neonates in Bangladesh
Principal Investigator: DR K Zaman Senior Scientist, ICDDRBCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 10 Oct, 2023
IV. A Phase IV open-label, randomized, parallel-group study to evaluate pharyngeal immunity to poliovirus type-2 in healthy bOPV- versus IPV-vaccinated infants
Principal Investigator: Dr K Zaman Senior Scientist ,icddrbCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 2 Oct, 2023
Showing 1 to 10 of 68 results
Login with Facebook
Login with Google